文献速递脑血管病

全国性队列中脑淀粉样血管病的患病率及后续缺血性/出血性卒中与死亡风险

Prevalence of Cerebral Amyloid Angiopathy and Associated Risk of Subsequent Ischemic and Hemorrhagic Stroke and Mortality in a Nationwide Cohort.
PubMed 文献 · Ann Neurol · 2025-05-01

基于美国5%全国医保样本2008–2022年理赔数据的回顾性队列研究,纳入1,920,312名Medicare受益人,其中2,161人(11.3/10,000)诊断为CAA。调整协变量后,CAA与死亡风险升高相关(HR 4.9;95%CI 4.6-5.2);在无卒中史者中,CAA与任何卒中(HR 8.0;95%CI 6.7-9.6)、缺血性卒中(HR 4.6;95%CI 3.6-6.0)、脑出血(HR 26.9;95%CI 20.3-35.6)及蛛网膜下腔出血(HR 21.6;95%CI 12.2-38.1)风险升高相关。

要点

  • 临床诊断CAA患病率约11.3/10,000(2,161/1,920,312)。
  • CAA与死亡风险升高相关(HR 4.9;95%CI 4.6-5.2)。
  • CAA与脑出血(HR 26.9;95%CI 20.3-35.6)及缺血性卒中(HR 4.6;95%CI 3.6-6.0)风险升高相关。

核心结论

  • 在大规模全国性Medicare受益人队列中,临床诊断CAA的患病率约为11/10,000。
  • CAA与死亡风险升高及新发卒中(出血性和缺血性)风险升高相关。

研究设计与样本

  • 回顾性队列研究,使用2008至2022年5%全国Medicare受益人住院和门诊理赔数据。
  • 样本共1,920,312名Medicare受益人,其中2,161人(11.3/10,000)诊断为CAA。
  • CAA从2015年10月1日至2022年确认,2008年至2015年9月30日数据用于确认合并症包括既往卒中。
  • 使用Cox回归分析CAA与后续死亡及新发卒中亚型的关联,调整人口学、血管危险因素和Charlson合并症。

主要发现

  • 调整Cox回归中,CAA与后续死亡相关(HR 4.9;95%CI 4.6-5.2)。
  • 在1,872,474名无既往卒中患者(包括900名CAA患者)中,CAA与任何卒中风险升高显著相关(HR 8.0;95%CI 6.7-9.6)。
  • CAA与缺血性卒中风险升高相关(HR 4.6;95%CI 3.6-6.0)。
  • CAA与脑出血风险升高相关(HR 26.9;95%CI 20.3-35.6)。
  • CAA与蛛网膜下腔出血风险升高相关(HR 21.6;95%CI 12.2-38.1)。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There are limited population-based data regarding the prevalence of cerebral amyloid angiopathy (CAA) and associated risks of mortality and incident cerebrovascular events. METHODS: We performed a retrospective cohort study using inpatient and outpatient claims from 2008 to 2022 from a 5% national sample of Medicare beneficiaries. CAA and ischemic and hemorrhagic stroke were identified using validated International Classification of Diseases 10th Revision (ICD-10) codes. We ascertained CAA from October 1, 2015 through 2022, and used data from 2008 through September 30, 2015 to ascertain comorbidities including prevalent stroke. We used Cox regression to examine the association of CAA with subsequent death and incident stroke subtypes after adjustment for demographics, vascular risk factors, and Charlson comorbidities. RESULTS: Among 1,920,312 Medicare beneficiaries in our sample, 2,161 (11.3 per 10,000) had a diagnosis of CAA. In adjusted Cox regression analysis, there was an association between CAA and subsequent mortality (HR 4.9; 95% CI 4.6-5.2). Among 1,872,474 patients without prevalent stroke, including 900 of the CAA patients, there was a significant association between CAA and an increased risk of any stroke (HR 8.0; 95% CI 6.7-9.6), ischemic stroke (HR 4.6; 95% CI 3.6-6.0), intracerebral hemorrhage (HR 26.9; 95% CI 20.3-35.6), and subarachnoid hemorrhage (HR 21.6; 95% CI 12.2-38.1). After a diagnosis of CAA, absolute risks of ischemic stroke and intracerebral hemorrhage were broadly similar. INTERPRETATION: In a large, nationwide cohort of Medicare beneficiaries, the prevalence of clinically diagnosed CAA was approximately 11 per 10,000. CAA was associated with an increased risk of mortality and incident stroke, both hemorrhagic and ischemic. ANN NEUROL 2025;98:249-257.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Bruce SS, Zhang C, Liberman AL, et al. Prevalence of Cerebral Amyloid Angiopathy and Associated Risk of Subsequent Ischemic and Hemorrhagic Stroke and Mortality in a Nationwide Cohort. Ann Neurol. 2025. PMID: 40309957. doi:10.1002/ana.27253

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。